首页> 外文OA文献 >RANDOMIZED, PARTIAL BLIND STUDY OF THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF MULTIPLE SUBCUTANEOUS DOSES OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ADMINISTERED EVERY 4 WEEKS ALONE OR IN COMBINATION WITH EZETIMIBE OR FENOFIBRATE IN HEALTHY SUBJECTS

【2h】

RANDOMIZED, PARTIAL BLIND STUDY OF THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF MULTIPLE SUBCUTANEOUS DOSES OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ADMINISTERED EVERY 4 WEEKS ALONE OR IN COMBINATION WITH EZETIMIBE OR FENOFIBRATE IN HEALTHY SUBJECTS

机译：随机，部分盲法研究阿鲁单抗的多种皮下注射剂量的药代动力学，药代动力学和安全性，该蛋白是人类完整的单克隆抗体，可转化为蛋白水解酶/胰蛋白酶，其大小为4或3，呈反义，单个或全部呈反义。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Rey Jacques; Poitiers Franck; Paehler Tobias; Brunet Aurelie; Pinquier Jean-Louis; Hanotin Corinne; Sasiela Bill;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co‐mixture with recombinant human hyaluronidase: A phase 1 randomized trial [J] . Almasa Bass, Anna Plotka, Khurshid Mridha, Health Science Reports . 2018,第9期

机译：与重组人透明质酸酶混合使用时，bococizumab（一种针对原蛋白转化酶枯草杆菌蛋白酶/ kexin型9的单克隆抗体）在健康受试者中的药代动力学，药效学和安全性：一项1期随机试验
2. Effects of 12weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin [J] . Fazio Sergio, Robertson David G., Joh Tenshang, Cardiovascular therapeutics . 2018,第1期

机译：静脉内施用的Bococizumab治疗12周，人源化单克隆抗体阻断先前蛋白转化酶枯草杆菌素/ kexin型9，高剂量毒素的高胆固醇对象
3. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive　― Results From a Randomized, Placebo-Controlled, Dose-Ranging Study ― [J] . Koutaro Yokote, Shigeto Kanada, Osamu Matsuoka, Circulation journal . 2017,第10期

机译：Bococizumab（RN316 / PF-04950615），一种针对原蛋白转化酶枯草杆菌蛋白酶/ Kexin 9型的单克隆抗体，在高胆固醇血症的日本受试者中接受稳定剂量的阿托伐他汀或未接受治疗的日本受试者的疗效和安全性来自随机，安慰剂对照的剂量-范围研究―
4. Pharmacokinetics pharmacodynamics and safety of bococizumab a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 in healthy subjects when administered in co‐mixture with recombinant human hyaluronidase: A phase 1 randomized trial [O] . Almasa Bass, Anna Plotka, Khurshid Mridha, 2018

机译：与重组人透明质酸酶混合使用时bococizumab（抗前蛋白转化酶枯草杆菌蛋白酶/ kexin型9的单克隆抗体）在健康受试者中的药代动力学药效学和安全性：一项1期随机试验
5. A RANDOMIZED STUDY OF THE RELATIVE BIOAVAILABILITY, PHARMACODYNAMICS, AND SAFETY OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, AFTER SINGLE SUBCUTANEOUS ADMINISTRATION AT THREE DIFFERENT INJECTION SITES IN HEALTHY SUBJECTS [O] . Lunven Catherine, Paehler Tobias, Lewanczyk Pascale, 2014

机译：多次连续三个剂量的单次连续给药后，对蛋白质的完全人类单克隆抗体阿洛洛单抗的相对生物利用度，药动学和安全性的随机研究。

著录项

引文网络

相似文献

相关主题

期刊订阅